• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by NRX Pharmaceuticals Inc.

    8/14/25 9:53:21 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NRXP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    NRX PHARMACEUTICALS, INC.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    629444209

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Anson Funds Management LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    IA, PN


    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Anson Management GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    TEXAS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    HC, OO


    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Tony Moore
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Anson Advisors Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    FI, CO


    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Amin Nathoo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP No.
    629444209


    1Names of Reporting Persons

    Moez Kassam
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,604,975.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,604,975.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,604,975.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.3 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NRX PHARMACEUTICALS, INC.
    (b)Address of issuer's principal executive offices:

    1201 Orange Street, Suite 600 Wilmington, DE 19801
    Item 2. 
    (a)Name of person filing:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam
    (b)Address or principal business office or, if none, residence:

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore: 16000 Dallas Parkway, Suite 800 Dallas, Texas 75248 For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam: 181 Bay Street, Suite 4200 Toronto, ON M5J 2T3
    (c)Citizenship:

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share
    (e)CUSIP No.:

    629444209
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Canadian Investment Advisor
    Item 4.Ownership
    (a)Amount beneficially owned:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 1,604,975 shares of Common Stock held by the Fund.
    (b)Percent of class:

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 9.3% of the outstanding shares of Common Stock held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo, and Mr. Kassam. This percentage is determined by dividing 1,604,975 by 17,289,192, which is the number of shares of Common Stock issued and outstanding, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Section 4(a)

     (ii) Shared power to vote or to direct the vote:

    See Section 4(a)

     (iii) Sole power to dispose or to direct the disposition of:

    See Section 4(a)

     (iv) Shared power to dispose or to direct the disposition of:

    See Section 4(a)

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See description regarding the Fund in the introduction, which is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Anson Advisors Inc. is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Anson Funds Management LP
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Management GP LLC
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Tony Moore
     
    Signature:/s/ Tony Moore
    Name/Title:Tony Moore, Manager
    Date:08/14/2025
     
    Anson Advisors Inc.
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
     
    Amin Nathoo
     
    Signature:/s/ Amin Nathoo
    Name/Title:Amin Nathoo, Director
    Date:08/14/2025
     
    Moez Kassam
     
    Signature:/s/ Moez Kassam
    Name/Title:Moez Kassam, Director
    Date:08/14/2025
    Get the next $NRXP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NRXP

    DatePrice TargetRatingAnalyst
    4/2/2025$18.00Buy
    BTIG Research
    More analyst ratings

    $NRXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider B Group, Inc. claimed ownership of 3,000,000 shares (SEC Form 3)

    3 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    8/21/25 6:21:37 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Abrams Michael S

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    2/11/25 5:00:05 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    12/18/24 8:27:36 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

    Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

    8/13/25 6:06:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

    WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

    8/11/25 4:05:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on NRx Pharmaceuticals with a new price target

    BTIG Research initiated coverage of NRx Pharmaceuticals with a rating of Buy and set a new price target of $18.00

    4/2/25 8:51:11 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    SEC Filings

    View All

    NRX Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 4:31:21 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by NRX Pharmaceuticals Inc.

    424B5 - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 8:01:41 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by NRX Pharmaceuticals Inc.

    10-Q - NRX Pharmaceuticals, Inc. (0001719406) (Filer)

    8/18/25 6:07:13 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and Chief Scientist Javitt Jonathan C bought $46,800 worth of shares (40,000 units at $1.17), increasing direct ownership by 90% to 84,634 units (SEC Form 4)

    4 - NRX Pharmaceuticals, Inc. (0001719406) (Issuer)

    12/18/24 8:27:36 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    9/13/22 4:47:33 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by NRX Pharmaceuticals Inc. (Amendment)

    SC 13D/A - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/17/22 5:00:47 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by NRX Pharmaceuticals Inc.

    SC 13D - NRX Pharmaceuticals, Inc. (0001719406) (Subject)

    6/3/22 3:59:15 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Financials

    Live finance-specific insights

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an "unmet medical need." This is a specific qualifying requirement for the Commissioner's National Priority Voucher Program.Filing of Commissioner's National Priority Voucher application for intravenous ketamine (NRX-100).Subm

    8/18/25 8:10:32 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Second Quarter 2025 Financial Results Release to August 19, 2025

    Conference Call 8:00am ET, Wednesday August 20, 2025 WILMINGTON, Del., Aug. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Tuesday, August 19, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.  The Company will host a conference call the following morning at 8:00am ET, Wednesday August 20, 2025. The Company requires addi

    8/13/25 6:06:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

    WILMINGTON, Del., Aug. 11, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its second quarter 2025 financial results after the market closes on Thursday, August 14, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. The Company will host a conference call at 4:30pm ET the same day. The call will provide a corporate and financial update, with a focus on recent regulatory events, regulatory strategy and go forward operational plans.   A live webcast of the conference call will be available on the Co

    8/11/25 4:05:00 PM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NRXP
    Leadership Updates

    Live Leadership Updates

    View All

    NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Join Fireside Chat at BTIG Virtual Biotech Conference July 29 - 30, 2025

    WILMINGTON, Del., July 29, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", or the "Company"), today announced that its CEO and Chairman will join a fireside chat at BTIG Virtual Biotechnology Conference on July 29 – 30, 2025. Prof. Jonathan Javitt, MD, MPH will join Prof. Samuel Wilkinson, MD, of the Yale School of Medicine, and  BTIG Research Analyst Dr. Thomas Shrader for a fireside chat to discuss neuroplasticity in the treatment of CNS disorders at 8:00 a.m. EDT on Wednesday, July 30, 2025. Prof. Wilkinson is a widely published psychiat

    7/29/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics

    Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwideKadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this spaceDr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPEMIAMI, May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ:NRXP), a clinic

    5/13/25 8:03:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc.

    WILMINGTON, Del., Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. Michael Taylor and Ms. Anita Nunes as Member and Observer of its Board of Directors, respectively.  Ms. Nunes is also to be appointed to the Board of Directors of Hope Therapeutics, Inc. Michael Taylor brings over 25 years of experience in global cr

    1/15/25 8:02:00 AM ET
    $NRXP
    Biotechnology: Pharmaceutical Preparations
    Health Care